Verapamil to preserve beta-cell function in newly diagnosed type 1 diabetes (Ver-A-T1D)
What this study tests
European Phase 2 trial of verapamil added to insulin in 136 newly diagnosed adults. Conference-reported results did not meet the primary intention-to-treat C-peptide endpoint. A positive per-protocol analysis is less conclusive and does not reverse that result; a full peer-reviewed outcome paper was not identified in this review.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-05-20.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults newly diagnosed with type 1 diabetes, enrolled within 6 weeks of starting insulin. Requires at least one diabetes autoantibody and some residual insulin production (fasting C-peptide above a minimum). Excludes pregnancy, significant heart/conduction problems, and existing use of calcium-channel blockers or interacting drugs. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- The EASD 2025 report states that the primary 12-month C-peptide comparison was not statistically significant, while a per-protocol analysis was positive. HbA1c improved only during the first six months; insulin requirements and overall glucose control were similar. Reported first-degree heart block (22%) and bradycardia (16%) were described as reversible with dose reduction. These are conference-reported findings, not a complete peer-reviewed safety assessment.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United Kingdom, European Union. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Primary endpoints
- Change in stimulated C-peptide area under the curve during a 2-hour mixed-meal tolerance test, from baseline to 12 months (verapamil vs placebo)
The full picture
Design
Ver-A-T1D randomized 136 newly diagnosed adults to sustained-release verapamil or placebo alongside insulin. It ran at 21 sites in six European countries. This is the European study NCT04545151, separate from earlier US adult and pediatric verapamil trials.32
Conference results and limits
The EASD 2025 report says the primary intention-to-treat C-peptide endpoint was not met. A positive per-protocol analysis excludes some randomized participants and is less conclusive. Investigators suggested slower-than-expected decline in the placebo group helped explain the result; this does not establish efficacy.2
First-degree heart block and bradycardia were reported and described as reversible with dose reduction. A complete peer-reviewed outcome report was not identified in this review.2
Sources
- [1]NCT04545151: study record · Trial registry — Current status, study design and eligibility checked 16 September 2026; this does not imply posted outcomes.
- [2]EASD: Ver-A-T1D conference results, September 2025 · Conference finding — EASD press release based on a conference presentation; a full outcome paper was not available with the release.
EASD, September 18, 2025 conference release.
- [3]Ver-A-T1D randomized trial protocol · Peer-reviewed study
Ver-A-T1D protocol, BMJ Open.